Infection

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

Retrieved on: 
Thursday, April 4, 2024
Escherichia coli, Central Bureau, Statistics, Burn, PCT, Shingles, Biotechnology, Growth, Disease, HIV, Klebsiella pneumoniae, COVID-19, Inhalation, HCMV, ASX, RCE, Recce, Viral, Pseudomonas aeruginosa, Virus, EBV, SARS-CoV-2, Staphylococcus aureus, Gonorrhea, Cytomegalovirus, Ross River virus, Neisseria meningitidis, GDP, Urinary tract infection, Skin, Streptococcus pyogenes, Patent, Staphylococcus, Streptococcus pneumoniae, Simplex, Infection, USD, Administration, Biology, Ageing, Pharmaceutical industry

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
  • “We are thrilled to have received this newly granted patent in Israel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Israel’s pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Immunocore to present at upcoming investor conferences

Retrieved on: 
Thursday, April 4, 2024
Patient, Infection, Cancer, Solid

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.

Key Points: 
  • (OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
  • & ROCKVILLE, Md., US, 04 April 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in April:
    Panel: T-Cell Engagers for Solid Tumors: Monday, April 15, 2024, at 4:00 p.m. EDT
    1x1 and small group meetings: Tuesday, April 16, 2024
    Where relevant, the presentations will be webcast live and can be accessed by visiting ‘Events’, under ‘News & Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com.
  • Following the event, a replay of the presentations will be made available for a limited time.

Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications

Retrieved on: 
Thursday, April 4, 2024
Disease, MSSA, MRSA, Development, TARGET, Associate, Partnership, CABP, New Drug Application, Patient, HHS, Mortality, NDA, Fungal infection, Staphylococcus aureus, Bronchopneumonia, Infection, Safety, SAB, ASPR, Staphylococcus, Ceftobiprole, Administration, FDA, ABSSSI, Pharmaceutical industry

David Veitch, Chief Executive Officer of Basilea, said: “We are excited with the US approval of ZEVTERA.

Key Points: 
  • David Veitch, Chief Executive Officer of Basilea, said: “We are excited with the US approval of ZEVTERA.
  • The positive decision by the FDA is a key milestone towards bringing ZEVTERA to patients in the US.
  • This approval is a landmark for ceftobiprole and reflects its broad clinical utility.
  • Through this partnership, Basilea has been awarded approximately USD 112 million, or approximately 75 percent of the costs related to the SAB and ABSSSI phase 3 studies, regulatory activities and non-clinical work.

Himax to Unveil Revolutionary Ultralow Power Contactless Palm Vein Authentication Technology, WiseEye Vein, at ISC West

Retrieved on: 
Wednesday, April 3, 2024
Venetian Expo, DNN, Arm, Certification, ICS, CMOS, Vein, Partnership, Risk, Level 2, AI, ISC, Semiconductor, Exhibition, Infection, Ecosystem, PSA

WiseEye Vein revolutionizes next-generation access control with its exceptionally low power consumption, making it possible for palm vein authentication to be applied in battery-powered endpoint devices.

Key Points: 
  • WiseEye Vein revolutionizes next-generation access control with its exceptionally low power consumption, making it possible for palm vein authentication to be applied in battery-powered endpoint devices.
  • WiseEye Vein is powered by Himax WiseEye AI solution featuring WiseEye2, Himax's second-generation AI processor, NIR CMOS image sensor, and proprietary AI inference model for palm vein authentication.
  • Meanwhile, WiseEye Vein offers exceptional accuracy compared to other biometric methods, due to the unique and intricate pattern of veins in the palm.
  • Himax invites all interested parties to stop by our exhibition at booth 4135 at Venetian Expo, Las Vegas during ISC West 2024.

BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, April 3, 2024
DFO, OrbiMed, NESS, Cystic Fibrosis Foundation, APT, FEV1, Part, Phage therapy, Patient, Orphan, KOL, Acquisition, Șaeș, Cystic fibrosis, Infection, Therapy, Pseudomonas aeruginosa, Pharmaceutical industry

CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 03, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Key Points: 
  • and NESS ZIONA, Israel, April 03, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Initial top line results of the Phase 2 trial are expected in the first quarter of 2025.
  • However, our financial statements contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.
  • ET to discuss its fourth quarter and full year 2023 financial results and to provide a corporate update.

Perma-Fix Successfully Completes Pilot Plant Testing and Unveils New Process for Destruction of PFAS “Forever Chemicals”

Retrieved on: 
Wednesday, April 3, 2024
AFFF, Pregnancy, Centofanti, Obesity, Pressure, PFAS, Incineration, Environment, Cancer, Water pollution, Puberty, Risk, Calcium fluoride, Research, History, PESI, Fertility, Prostate, Commercial, Human, Chemistry, Infection, Ecosystem, Water, Kidney, Patent, Biosolids, Government, Cosmetics

Present disposal options for PFAS liquids include deep wells, incineration and landfills, all of which have serious environmental liability issues.

Key Points: 
  • Present disposal options for PFAS liquids include deep wells, incineration and landfills, all of which have serious environmental liability issues.
  • We expect that the Perma-Fix’s process will virtually eliminate PFAS compounds (minimum of 99.9999% destruction) and reduces the environmental liability associated with these materials.
  • Additionally, the process is designed to operate at a highly competitive price compared to traditional disposal options.
  • According to a recent article in Barron’s the estimated cleanup cost for PFAS compounds could exceed $200 billion.

60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis

Retrieved on: 
Wednesday, April 3, 2024
Tafenoquine, Food and Drug Administration, Infection, Food, FDA, Babesiosis, Dog, Malaria

WASHINGTON, April 03, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the Company will sponsor a pilot study of tafenoquine, the active molecule in its U.S. Food and Drug Administration (FDA)-approved human malaria prevention medication, ARAKODA®, for the treatment of babesiosis in dogs.

Key Points: 
  • WASHINGTON, April 03, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the Company will sponsor a pilot study of tafenoquine, the active molecule in its U.S. Food and Drug Administration (FDA)-approved human malaria prevention medication, ARAKODA®, for the treatment of babesiosis in dogs.
  • The study will support a broader effort now being led by 60 Degrees Pharmaceuticals to evaluate tafenoquine for various babesiosis indications.
  • Tafenoquine has not been proven to be effective for treatment or prevention of canine babesiosis and is not approved by the FDA for such an indication.

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

Retrieved on: 
Wednesday, April 3, 2024
Clobetasol, Exchange, Infection, Acceleration, Refractive surgery, Inflammation, Annual general meeting, ASCRS, Patient, Private practice, Cataract, Society, Ophthalmology

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced that the company will be conducting demonstrations of its portfolio of commercial products at two upcoming ophthalmology medical meetings.

Key Points: 
  • “Our presence at national medical and commercial meetings like these are key to elevating awareness of our continuum of office-based and surgical products,” stated Michael Rowe, Eyenovia’s Chief Executive Officer.
  • These meetings complement the efforts of our field sales force in amplifying the synergistic nature of our product portfolio as well as the many benefits conferred to doctors and patients by the Optejet device.
  • Eyenovia will also be demonstrating Avenova and reviewing now-approved data on clobetasol, which complements the company’s surgical suite of products.
  • The event features continuing education, keynote speakers, Exchange-only pricing from more than 100 vendors, and opportunities to network with colleagues.

Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.

Retrieved on: 
Tuesday, April 2, 2024
Infection, OTCQX, Therapy, Bank, LZH, Arrangement, Calendar, Health, Public, Research, News, Acquisition, TSX, Drug development, Population health, Canada Business Corporations Act, Transaction, Growth, Entrepreneurship, Share, Procurement, CDN, Security (finance)

HALIFAX, Nova Scotia, April 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that it has entered into a definitive arrangement agreement (the "Arrangement Agreement") pursuant to which Aditxt Inc. (NASDAQ: ADTX) (“Aditxt”), a Richmond, Virginia- based company dedicated to discovering, developing, and deploying promising health innovation, through its wholly-owned subsidiary, Adivir, Inc. (“Adivir” or the “Buyer”), agreed to acquire all of the issued and outstanding Class A common shares (the "Appili Shares") of Appili by way of a court-approved plan of arrangement under the Canada Business Corporations Act (the "Transaction").

Key Points: 
  • We welcome this new chapter, confident that together, we will achieve even greater heights in deploying innovative healthcare solutions.” said Dr. Don Cilla, President and CEO of Appili Therapeutics.
  • Under the terms of the Arrangement Agreement, Adivir will acquire all of the issued and outstanding Appili Shares, with each Appili Shareholder receiving the Transaction Consideration.
  • The Transaction is subject to the approval of at least two-thirds of the votes cast by the Appili Shareholders at the Appili Meeting.
  • Bloom Burton Securities Inc. acted as financial advisor to the Appili Board and BDO Canada LLP acted as independent financial advisor to the Appili Special Committee.

Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

Retrieved on: 
Tuesday, April 2, 2024
COVID19, COVID, Trawsfynydd, Pfizer, Drug, Novartis, General partnership, Patient, CYP, Oseltamivir, CDK, Aes, Ritonavir, SARS-CoV-2, Delta, Infection, Viral disease, Omicron, Therapy, OrbiMed, Safety, Pharmacokinetics, Toxicology, Lilly, Bone marrow suppression, CSO, GLP, Mergers and acquisitions, Pharmaceutical industry

Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)

Key Points: 
  • Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)
    Companies to host joint webcast, April 2, 2024 at 8:30 a.m.
  • Under the terms of the agreement, Onconova acquired 100% of Trawsfynydd’s outstanding equity interests.
  • These proceeds will be used to advance the Traws’ programs through multiple clinical data catalysts and complete the dose ranging study for narazaciclib.
  • Topline data are expected H2 2024
    Phase 2 study planned to be initiated in H2 2024.